MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.93 -0.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.64

Max

28.4

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	9.926 56.063
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+53.35% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	8.3M 1.6B
Ankstesnė atidarymo kaina	28.07
Ankstesnė uždarymo kaina	27.93

Naujienos nuotaikos

By Acuity

50%

163 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-01 22:56; UTC

Svarbiausios naujienos

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026-04-01 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026-04-01 23:55; UTC

Rinkos pokalbiai

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026-04-01 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026-04-01 23:23; UTC

Svarbiausios naujienos

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026-04-01 23:07; UTC

Uždarbis

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026-04-01 23:02; UTC

Svarbiausios naujienos

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026-04-01 23:00; UTC

Svarbiausios naujienos

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026-04-01 23:00; UTC

Svarbiausios naujienos

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026-04-01 23:00; UTC

Svarbiausios naujienos

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026-04-01 22:39; UTC

Uždarbis

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026-04-01 22:08; UTC

Rinkos pokalbiai

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026-04-01 22:00; UTC

Svarbiausios naujienos

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026-04-01 22:00; UTC

Svarbiausios naujienos

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026-04-01 21:56; UTC

Įsigijimai, susijungimai, perėmimai

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026-04-01 21:31; UTC

Svarbiausios naujienos

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-01 20:38; UTC

Uždarbis

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026-04-01 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026-04-01 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026-04-01 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026-04-01 20:13; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026-04-01 20:07; UTC

Rinkos pokalbiai

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

53.35% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 53.35%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

163 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.